Bartos Csilla, Varga Patrícia, Szabó-Révész Piroska, Ambrus Rita
Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 6726 Szeged, Hungary.
Pharmaceutics. 2021 Apr 22;13(5):608. doi: 10.3390/pharmaceutics13050608.
The absorption of non-steroidal anti-inflammatory drugs (NSAIDs) through the nasal epithelium offers an innovative opportunity in the field of pain therapy. Thanks to the bonding of chitosan to the nasal mucosa and its permeability-enhancing effect, it is an excellent choice to formulate microspheres for the increase of drug bioavailability. The aim of our work includes the preparation of spray-dried cross-linked and non-cross-linked chitosan-based drug delivery systems for intranasal application, the optimization of spray-drying process parameters (inlet air temperature, pump rate), and the composition of samples. Cross-linked products were prepared by using different amounts of sodium tripolyphosphate. On top of these, the micrometric properties, the structural characteristics, the in vitro drug release, and the in vitro permeability of the products were studied. Spray-drying resulted in micronized chitosan particles (2-4 μm) regardless of the process parameters. The meloxicam (MEL)-containing microspheres showed nearly spherical habit, while MEL was present in a molecularly dispersed state. The highest dissolved (>90%) and permeated (~45 µg/cm) MEL amount was detected from the non-cross-linked sample. Our results indicate that spray-dried MEL-containing chitosan microparticles may be recommended for the development of a novel drug delivery system to decrease acute pain or enhance analgesia by intranasal application.
非甾体抗炎药(NSAIDs)通过鼻黏膜上皮的吸收为疼痛治疗领域提供了一个创新机会。由于壳聚糖与鼻黏膜的结合及其渗透增强作用,它是制备微球以提高药物生物利用度的绝佳选择。我们工作的目的包括制备用于鼻内应用的喷雾干燥交联和非交联壳聚糖基药物递送系统,优化喷雾干燥工艺参数(进气温度、泵速)以及样品组成。通过使用不同量的三聚磷酸钠制备交联产物。除此之外,还研究了产物的微观特性、结构特征、体外药物释放和体外渗透性。无论工艺参数如何,喷雾干燥均产生了微粉化的壳聚糖颗粒(2 - 4μm)。含美洛昔康(MEL)的微球呈现出近似球形的形态,而MEL以分子分散状态存在。从非交联样品中检测到的MEL溶解量最高(>90%)且渗透量最高(~45μg/cm)。我们的结果表明,喷雾干燥的含MEL壳聚糖微粒可能推荐用于开发新型药物递送系统,通过鼻内应用减轻急性疼痛或增强镇痛效果。